Overview

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
David Baskin MD
Collaborator:
Center for Cell and Gene Therapy, Baylor College of Medicine
Treatments:
Acyclovir
Valacyclovir